Resources
Condition Outcomes
The document summarises the outcomes of conditions identified through the pre-assessment process for Australia's Newborn Bloodspot Screening program. It displays this information as a table with condition name and the outcome of that condition.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 9 October 2026
The 'LSDP Expert Panel 24th meeting 9 October 2026 - web agenda' provides the agenda of the LSDP Expert Panel meeting on the 9 October 2026.
Infection prevention and control principles and recommendations for Ebola virus disease
This document is to describe actions and measures recommended to protect healthcare workers (HCWs) and others who may come in contact with Ebola virus, or patients with suspected or confirmed Ebola virus disease (EVD).
Ministerial Expert Panel on Women’s Health communiqué – 3 August 2026
The fourth meeting of the Ministerial Expert Panel on Women's Health focused on how primary care can better support women's cardiovascular health.
Ministerial Expert Panel on Women’s Health communiqué – 6 July 2026
The third meeting of the Ministerial Expert Panel on Women's Health focused on how sex and gender are considered in health research and in the approval of medicines, health technologies and health services for cardiovascular disease and stroke.
Newborn bloodspot screening (NBS) – National implementation timeframes for new conditions fact sheet
This fact sheet outlines the key steps and timeframes for adding new conditions to NBS programs to support the safe and consistent expansion of NBS in Australia.
New arrangements for nitisinone (Orfadin®) – information for prescribers
This fact sheet is for current prescribers (treating physicians) with patients requiring treatment for hereditary tyrosinaemia type 1. It explains how a treatment for this condition, nitisinone (Orfadin®), will be transitioning from the Life Saving Drugs Program to the PBS.
New arrangements for nitisinone (Orfadin®) – Treatment of hereditary tyrosinaemia type 1 – information for patients
This fact sheet is for current and future patients with hereditary tyrosinaemia type 1 explaining how a treatment for this condition, nitisinone (Orfadin®), will be transitioning from the Life Saving Drugs Program to the PBS. It provides further clarity on future access arrangements via the PBS.
Life Saving Drugs Program (LSDP) Expert Panel meeting update – 19 June 2026
Provides an update, cancellation, to the planned meeting of the Life Saving Drugs Program Expert Panel meeting that was due to be held on 19 June 2026.
National Cancer Screening Register – Privacy Impact Assessment for Data Linkage Projects
This report considers the privacy impacts of linking data from the National Cancer Screening Register with data from the Australian Bureau of Statistics’ Person Level Integrated Data Asset and the Australian Institute of Health and Welfare’s National Health Data Hub.
Australian Government Response to the Standing Committee report – The state of diabetes mellitus in Australia in 2024
Read the Australian Government's response to the House of Representatives Standing Committee on Health, Aged Care and Sport report on The State of Diabetes Mellitus in Australia in 2024.
X-linked adrenoleukodystrophy (X-ALD) summary of ethical considerations and social acceptability of NBS for females
This publication presents a summary of the work undertaken to examine the ethical considerations and social acceptability of screening X-linked adrenoleukodystrophy (X-ALD) in female newborns.
04:15
Chief Medical Officer Professor Michael Kidd - Address on the National Strategic Framework for Chronic Conditions and grants program
Listen to Chief Medical Officer Professor Michael Kidd discuss the National Strategic Framework for Chronic Conditions and the related Chronic Conditions Prevention and Integrated Care Grants Program.
Application Form A for Conditions Group 1 – Inborn Errors of Metabolism
Application for Australian Government financial assistance for individuals with Inborn Errors of Metabolism — DHPR, hyperphenylalaninemia and PKU conditions only. For other conditions, use Application Form B.
National Parkinson's Action Plan
The National Parkinson’s Action Plan is the result of people with Parkinson’s making their voices heard. It aims to support improved responses to the needs of the Parkinson’s community through better care and support for people with Parkinson’s, along with their families and carers.
National Strategic Framework for Chronic Conditions
The National Strategic Framework for Chronic Conditions 2026–2035 sets Australia’s long term plan to prevent and manage chronic illness. It guides governments, health services and communities to work together, focusing on prevention, integrated care, equity and shared risk factors.
Chronic Conditions Prevention and Integrated Care Program – Overview
Learn about the new Chronic Conditions Prevention and Integrated Care Program. It funds evidence‑based prevention, early detection and integrated care through national grants to improve outcomes and reduce health inequities.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 13 March 2026
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 23rd meeting on 13 March 2026.
Life Saving Drugs Program (LSDP) – Olipudase alfa (Xenpozyme®) outcome statement
Summary of the consideration of the application from Sanofi Australia and New Zealand for the inclusion of olipudase alfa (Xenpozyme®) on the LSDP for the treatment of acid sphingomyelinase deficiency (ASMD) types A/B and B.
Newborn bloodspot screening (NBS) – Our national decision-making pathway fact sheet
This fact sheet provides information on the national NBS decision-making pathway, including the role of each committee in the process.
Newborn bloodspot screening (NBS) – Delivering consistency and expansion fact sheet
This fact sheet provides information about what NBS expansion means for families and consumers, expansion progress to date, and upcoming milestones.
02:20
Newborn Bloodspot Screening Open Call
Newborn bloodspot screening programs improve the health of babies by identifying those at risk of developing serious conditions. An open call inviting the public to identify conditions for consideration for screening was open from 14 October 2025 and closed on 14 January 2026.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 31 October 2025
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 22nd meeting on 31 October 2025.
MyMedicare and Chronic Condition Management MBS items and Patient Case Studies
Changes to the MBS Chronic Condition Management Framework from 1 July 2025, aim to support high quality, continuous, multidisciplinary team-based care for patients.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 25 July 2025
Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 21st meeting on 25 July 2025.
Date last updated: